Corcept Therapeutics Inc is a biopharmaceutical company based in Menlo Park, California, focusing on the development of drugs to treat severe disorders such as endocrinologic, oncologic, metabolic, and neurologic conditions. Its flagship product, Korlym, helps manage hyperglycemia caused by Cushing's syndrome. The company is also advancing a robust pipeline, including relacorilant for Cushing's syndrome and other candidates targeting adrenal cancer, prostate cancer, ovarian tumors, amyotrophic lateral sclerosis, nonalcoholic steatohepatitis, and antipsychotic-induced weight gain, with several treatments in late-stage clinical trials.
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire…
Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD | FOLD Price Prediction) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum. Corcept posted revenue…
